tbuckley/cabot-search huggingface dataset:
Tissue reservoirs of antiviral T cell immunity in persistent human CMV infection
Authors: Claire L. Gordon, Michelle Miron, Joseph J.C. Thome, Nobuhide Matsuoka, Joshua Weiner, Michael A. Rak, Suzu Igarashi, Tomer Granot, Harvey Lerner, Felicia Goodrum, Donna L. Farber
Journal: The Journal of Experimental Medicine (2017)

T cell responses to viruses are initiated and maintained in tissue sites; however, knowledge of human antiviral T cells is largely derived from blood. Cytomegalovirus (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses remain undefined. Here, we investigated human CMV-specific T cells, virus persistence and CMV-associated T cell homeostasis in blood, lymphoid, mucosal and secretory tissues of 44 CMV seropositive and 28 seronegative donors. CMV-specific T cells were maintained in distinct distribution patterns, highest in blood, bone marrow (BM), or lymph nodes (LN), with the frequency and function in blood distinct from tissues. CMV genomes were detected predominantly in lung and also in spleen, BM, blood and LN. High frequencies of activated CMV-specific T cells were found in blood and BM samples with low virus detection, whereas in lung, CMV-specific T cells were present along with detectable virus. In LNs, CMV-specific T cells exhibited quiescent phenotypes independent of virus. Overall, T cell differentiation was enhanced in sites of viral persistence with age. Together, our results suggest tissue T cell reservoirs for CMV control shaped by both viral and tissue-intrinsic factors, with global effects on homeostasis of tissue T cells over the lifespan.
NCO-17A BRAIN-PLASTICITY BASED COMPUTERIZED INTERVENTION TO TREAT ATTENTION AND MEMORY PROBLEMS IN ADULT BRAIN TUMOR (BT) SURVIVORS
Authors: Jeffrey Wefel, Mariana Bradshaw, Catherine Sullaway, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2015)

BACKGROUND: BT survivors commonly have impairments in attention/memory that adversely impact independence, home, school and work roles, mood and quality of life. Adults produce new brain cells, replace dead brain cells, and adaptively recruit new brain regions to perform certain tasks. We sought to determine the feasibility, acceptability, and early efficacy signals of an at-home, internet accessible, adaptive, brain-plasticity based computerized intervention designed to enhance attention/memory processes (Plasticity-based Adaptive Cognitive Remediation, PACR). METHODS: Adult BT survivors with self-reported and tested attention/memory impairment, status post surgery and radiation were enrolled (n = 34) into a longitudinal, single-arm study. Patients completed neuropsychological testing before and after intervention. Patients were instructed to complete 40 PACR sessions (1 hour/day, 5 days/week for 8 weeks). A priori feasibility was defined as >80% of patients completing >10 sessions in the first month and not skipping >10 consecutive sessions thereafter. Secondary objectives were to assess improvement on trained tasks (near transfer), unrelated cognitive tests (far transfer), and acceptability. RESULTS: PACR was considered feasible in 40% of patients; 77% reported being somewhat or very satisfied with PACRs usefulness in helping to minimize the impact of cognitive symptoms on ability to function effectively in daily activities; and 100% of subjects would recommend PACR to others. Near transfer of training effects were significant (P < 0.05) on most trained tasks with effect sizes ranging from 0.32 to 1.29. Far transfer of training effects were only seen on the COWA (p = 0.02). CONCLUSIONS: Only 40% of BT survivors completed the PACR intervention as it was prescribed in this study. Near transfer of training but not far transfer of training was observed. Most participants found the intervention useful and all would recommend it to other patients. Consideration of dose-response curves, alternative treatment delivery, and patient selection appears warranted if PACR is to be a viable intervention.
Generation, Functional Characterization and Clinical Application of a Novel Fc-Optimized Anti-FLT3 Antibody for the Treatment of Acute Myeloid Leukemia
Authors: Helmut R. Salih, Tina Baessler, Martin Hofmann, Ludger Grosse-Hovest, Maximilian Bamberg, Steffen Aulwurm, Hans-Joerg Buehring, Lothar Kanz, Gundram Jung
Journal: Blood (2010)
FCgammaRIIa Polymorphism Is Not Associated with Overall Response, Progression Free Survival and Overall Survival In Diffuse Large B-Cell Lymphoma Treated with Rituximab
Authors: Marcelo Bellesso, Sergio Paulo Bydlowski, Renata Oliveira Costa, Felipe Vieira Rodrigues Maciel, Debora Levy, Juliana Pereira
Journal: Blood (2010)
R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study
Authors: Luigi Rigacci, Alberto Fabbri, Benedetta Puccini, Enrico Orciuolo, Alice Pietrini, Lorenzo Iovino, Mario Petrini, Francesco Lauria, Alberto Bosi
Journal: Blood (2011)
Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells
Authors: Aaron P. Rapoport, Nicole A. Aqui, Edward A. Stadtmauer, Ashraf Z. Badros, Dan T. Vogl, YinYan Xu, Brendan M Weiss, Ling Cai, Hong-Bin Fang, Elizabeth Veloso, Zhaohui Zheng, Saul Yanovich, Gorgun Akpek, Sunita Philip, Kathleen Ruehle, Kelly-Marie Betts, Anne Chew, Holly McConville, Sandra Westphal, Scott Strome, Andres Salazar, Bruce L. Levine, Carl H. June
Journal: Blood (2012)
Phase II Study of Oral Fludarabine (FAMP) in Combination with Rituximab in Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL)
Authors: Kenichi Ishizawa, Kensei Tobinai, Michinori Ogura, Kuniaki Itoh, Yasuo Morishima, Kiyoshi Ando, Joji Yamamoto, Takashi Watanabe, Toshiki Uchida, Masanobu Nakata, Masaki Hayashi, Tomomitsu Hotta
Journal: Blood (2007)
Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer.
Authors: S. Matsusaka, K. Chin, N. Mizunuma, M. Ogura, M. Suenaga, M. Ozaka, K. Takagi, M. Oba, Y. Mishima, K. Hatake
Journal: Journal of Clinical Oncology (2011)

43 Background: The purpose of this study was to quantify circulating tumor cells (CTCs) in advanced gastric cancer (AGC) patients, and to demonstrate the role of CTCs in cancer therapy. The purpose of this study was to identify CTC threshold proposal for determining response to chemotherapy in AGC. Methods: From November 2007 to June 2009, fifty-two patients with AGC were enrolled into a prospective study. All patients were enrolled using institutional review board-approved protocols at the Cancer Institute Hospital and provided informed consent. The study population consisted of patients of aged 18 years or older with histologically proven AGC. Other inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2; adequate organ function. The subjects were five patients treated with S-1 (40 mg/m 2 , twice daily, days 1-28, repeated every 6 weeks), twenty-six patients treated with S-1 plus CDDP (S-1 40 mg/m 2 , twice daily, days 1-21, CDDP 60 mg/m 2 , day 8, repeated every 5 weeks), and twenty-one patients treated with paclitaxel (80 mg/m 2 , weekly). CTCs of whole blood at baseline, two weeks and four weeks after initiation of chemotherapy, were isolated and enumerated using immunomagnetics. Results: Patients with ≥4 CTCs at two-week points and four-week points had a shorter median PFS (1.4, 1.4 months, respectively), than those with the median PFS of &lt;4 CTCs (4.9, 5.0 months, respectively) (p&lt;0.001, p&lt;0.001, respectively). Patients with ≥4 CTCs at two-week points and four-week points had shorter median OS (3.5, 4.0 months, respectively) than those with the median PFS of &lt;4 CTCs (11.7, 11.4 months, respectively) (p&lt;0.001, p=0.001, respectively). In univariate analysis, PS, treatment regimen, Line of chemotherapy, and CTC levels at 2 weeks and 4 weeks predicted PFS and OS. In order to evaluate the independent predictive effect of chemotherapy, multivariate Cox regression analysis was carried out. CTC levels at 2 weeks and 4 weeks were the strongest predictors. Conclusions: A threshold of lower than 4 CTC/7.5 ml at 2 weeks and 4 weeks was a significant predictor of the outcome for AGC patients treated with S-1 based regimen or paclitaxel regimen. No significant financial relationships to disclose.
Distinction of Early and Late Molecular Events In Patients with Myelodysplastic Syndromes (MDS) Who Progressed to Acute Myeloid Leukemia (AML),
Authors: Manuel G Afable, Hideki Makishima, Hirotoshi Sakaguchi, Andres Jerez, Anna Malgorzata Jankowska, Kathryn M Guinta, Sara Abu Kar, Fabiola Traina, Yuka Sugimoto, Christine O'Keefe, Ramon V. Tiu, Mikkael A. Sekeres, Jaroslaw P Maciejewski
Journal: Blood (2011)
Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression.
Authors: Grant Duncan Stewart, Fiach O'Mahony, Lel Eory, Jyoti Nanda, Alexander Laird, Marie O'Donnell, Peter Mullen, Antony Riddick, Alan McNeill, Michael Aitchison, Dan Berney, John Peters, Andrea Rockall, Anju Sahdev, Axel Bex, Dana Faratian, Simon Chowdhury, David Harrison, Ian Overton, Thomas Powles
Journal: Journal of Clinical Oncology (2012)

388 Background: To investigate acquired resistance of clear cell renal cell cancer (ccRCC) patients to sunitinib and develop personalised treatment strategies, sequential tissue after a specific period of targeted therapy is required. This approach has proven successful with targeted therapy in chronic myeloid leukaemia; however, we are concerned that extensive tumour heterogeneity occurs in ccRCC. In this study we evaluated heterogeneity and differential protein expression in sunitinib treated and untreated ccRCC samples using high-throughput proteomics. Methods: Fresh frozen tissue was obtained from 27 sunitinib naïve ccRCC specimens and 27 nephrectomy samples from patients treated with neoadjuvant sunitinib (18 weeks) as part of the SuMR trial. From each tumour frozen sections were performed and up to 5 protein lysates obtained from each morphologically differing region of each tumour as well as matched normal kidney. Reverse phase protein arrays (RPPA) were performed to assess the levels of multiple proteins relevant to ccRCC pathogenesis and sunitinib activity. Appropriate statistical tests were used to examine protein heterogeneity and differential expression, including false discovery rate (FDR) correction. Kaplan-Meier method was used to correlate changes in protein expression with outcome. Results: Expression of 20 proteins has been examined to date. The range of expression in tumours normalised by matched normal renal tissue had &gt;2-fold differences in untreated (n=8 proteins) and treated samples (n=4 proteins). Four markers displayed significantly increased inter-tumoural variance in sunitinib treated tumours compared with untreated tissue (e.g. VEGFR1, FDR P&lt;0.05). Despite this heterogeneity, sunitinib was associated with significant expression changes for several key proteins (e.g. VEGFR2, CyclinD2; FDR P&lt;0.05). Conclusions: Protein expression in ccRCC is heterogenous and key proteins showed significantly increased variance of expression with sunitinib therapy. Despite heterogeneity, significant changes in protein expression can be identified with sunitinib treatment and have been correlated with outcome.
Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).
Authors: Erica Linden, Steven L. McAfee, Bimalangshu R. Dey, Karen Ballen, Susan Saidman, Christine Colby, Megan Sykes, Thomas R. Spitzer
Journal: Blood (2005)
Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models
Authors: Changchun Deng, Peter Sportelli, Richard Rodriguez, Hari Miskin, Swaroop Vakkalanka, Srikant Viswanadha, Owen A. O'Connor
Journal: Blood (2012)
Targeting Cdk4/6 in Combination Therapy Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma through Synergistic Mitochondria Depolarization.
Authors: Xiangao Huang, Tracey Louie, Maurizio Di Liberto, Jun Rice, David Jayabalan, Kang Zhang, Michael Palladino, Isan Chen, Peter Toogood, Ruben Niesvizky, Malcolm A.S. Moore, Selina Chen-Kiang
Journal: Blood (2007)
CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia
Authors: Jae-Woong Lee, Zhengshan Chen, Huimin Geng, Gang Xiao, Eugene PARK, Samir Parekh, Steven M. Kornblau, Ari Melnick, Abul Abbas, Elisabeth Paietta, Markus Muschen
Journal: Blood (2015)
ATPS-86MUTATIONS IN THE EGF RECEPTOR EXTRACELLULAR DOMAIN REVEAL AN UNTETHERED TRANSITIONAL STATE WHICH MEDIATES mAb806 BINDING
Authors: Amy Haseley Thorne, Laura Orellana, Alison Parisian, Webster Cavenee, Frank Furnari
Journal: Neuro-Oncology (2015)

The epidermal growth factor receptor (EGFR) is both amplified and frequently mutated in glioblastoma. While downstream inhibition of EGFR signaling through small molecule tyrosine kinase inhibitors has shown little clinical efficacy in glioblastoma, monoclonal antibody targeting is proving to be a promising alternative. The monoclonal antibody 806 (mAb806) specifically binds the most common EGFR mutant, EGFRvIII, along with a subset of amplified wild type EGFR, but not EGFR expressed at normal levels. The selectivity of mAb806 is thought to be due to its targeting a tumor-specific epitope of EGFR which is only accessible as the receptor transitions between an inactive tethered conformation to an active ligand-bound dimer. Here we used molecular dynamics simulations coupled with in vitro assays in glioblastoma cells to characterize the transitional conformation of EGFR in mAb806 binding. Focusing on the mutations R108K and G63R, molecular dynamics simulation revealed a spontaneous untethering of EGFR to a compact conformation, which is characterized by a backwards rotation of domain I-II exposing both the dimerization arm and the mAb806-epitope. This configuration is structurally equivalent to EGFRvIII, suggesting that several glioblastoma mutations converge to remove domain I from the dimerization interface. Next, we evaluated the effect of these point mutations on the ability of mAb806 to bind glioblastoma cells in vitro. Using site-directed mutagenesis coupled with lentiviral-transduction, we expressed EGFR-R108K or EGFR-G63R in U87 glioblastoma cells. Investigating mAb806 binding by FACS, we show that mAb806 binds the mutant cells five times greater than control cells, validating our simulation predictions. Future studies will examine the effect of mAb806 in an in vivo tumor model. Significantly, as these point mutations have been found in several GBM patients, our results indicate the possibility of a broader patient spectrum for the use of ABT-806, a humanized version of mAb806 currently in phase I clinical trials.
Assessing the Utility of Transcatheter Aortic Valve Replacement
Authors: Karen P. Alexander
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Different Kinetics and Function of Vascular Endothelial Growth Factor Recepotor-1 and −2 during Hemangioblast Development from Primate Embryonic Stem Cells.
Authors: Katsutsugu Umeda, Toshio Heike, Gen Shinoda, Akira Niwa, Masato Arai, Hiroshi Matsubara, Feng Ma, Souichi Adachi, Hirofumi Suemori, Ryuzo Torii, Masabumi Shibuya, Norio Nakatsuji, Tatsutoshi Nakahata
Journal: Blood (2006)
Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children’s Oncology Group study
Authors: Wendy Landier, Yanjun Chen, Lindsey Hageman, Heeyoung Kim, Bruce C. Bostrom, Jacqueline N. Casillas, David S. Dickens, William E. Evans, Kelly W. Maloney, Leo Mascarenhas, A. Kim Ritchey, Amanda M. Termuhlen, William L. Carroll, Mary V. Relling, F. Lennie Wong, Smita Bhatia
Journal: Blood (2017)
Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes
Authors: Michaela Cada, Catherine I. Segbefia, Robert J. Klaassen, Conrad V Fernandez, Rochelle Yanofsky, John K. Wu, Josette Champagne, Mariana Silva, Jeffrey H. Lipton, Josee Brossard, Yvan Samson, Sharon Abish, MacGregor Steele, Kaiser Ali, Nancy Dower, Uma Athale, Lawrence Jardine, Lisa Goodyear, Isaac Odame, Patricia Canning, Bozana Zlateska, Lillian Sung, Joseph Beyene, Yigal Dror
Journal: Blood (2012)
Lack of Binding of Monoclonal Protein Produced by Multiple Myeloma (MM) Cells to FcγRIIb Reduces Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling and Provides the Rationale for a Novel Therapeutic Approach to MM
Authors: Jennifer Li, Mingjie Li, Cathy Wang, Jessica Wang, Eric Sanchez, Zhi-Wei Li, Benjamin Bonavida, Haiming Chen, James R. Berenson
Journal: Blood (2010)
ATNT-29TREATMENT OF GLIOBLASTOMA: USE OF BEVACIZUMAB AFTER FIRST PROGRESSION. EXPERIENCE OF 20 DE NOVIEMBRE ISSSTE MEDICAL CENTER, MEXICO CITY
Authors: Josué Mora Pérez, Alejandro Juárez Ramiro, Aura Erazo Argentina Valle Solls
Journal: Neuro-Oncology (2015)

In Mexico the incidence of brain tumors was 4786 cases in 2012, 18% of these tumors are glioblastoma, The study was conducted January 2007 to April 2015, with patients diagnosed with glioblastoma, included in the study, after standard treatment (CT/RT) and adjuvant temozolamide. Patients remained under surveillance with IMR. If progression was detected, bevacizumab was initiated at 10mg/Kg until progression; if patient had a good performance after the use of bevacizumab, we added Irinotecan and continued bevacizumab. The primary end point was progression-free survival, the secondary objective was overall survival. Inclusion criteria: Patients diagnosed with glioblastoma, age ≥ 18 years, ECOG 0-2, Karnofsky> 70. Exclusion criteria: Patients without diagnosis of glioblastoma ECOG 3. MATERIALS AND METHODS: 84 cases diagnosed with brain tumors, only 24 patients have glioblastoma. RESULTS: Age was 50 years, 10 women and 14 men, 2 patients with complete resection, 1 with biopsy and 21 remaining with partial resections were 40-80% of the tumor, DFS was 12. 7 months, with an overall survival of 31 months, 8 patients continued bevacizumab and irinotecan after second progression. DISCUSSION: This is the first Mexican study of reported experience with the use of bevacizumab, median overall survival 31 months, with a mean PFS of 12.7 months. We do not make the determination of IDH1, but the benefit of use of bevacizumab after the first progression and continue after second progression exist. we need a biomarker and clinical parameter. CONCLUSIONS: The use of bevacizumab in patients with glioblastoma has free survival similar to other reports, is safe in Mexican population, and some patients receive CT and continue to bevacizumab with increase of OS.
Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.
Authors: Joseph D. Growney, Peter Atadja, Wenlin Shao, Youzhen Wang, Minying Pu, Brant Firestone, Jane Cheng, Colleen Kowal, Christine Miller, Joseph Eckman, Yung-Mae Yao, Stephen Fawell, Andrew Spencer, Jesus F. San Miguel, Kenneth C. Anderson
Journal: Blood (2007)
Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations
Authors: Tie Zheng Hou, Nisha Verma, Jennifer Wanders, Alan Kennedy, Blagoje Soskic, Daniel Janman, Neil Halliday, Behzad Rowshanravan, Austen Worth, Waseem Qasim, Helen Baxendale, Hans Stauss, Suranjith Seneviratne, Olaf Neth, Peter Olbrich, Sophie Hambleton, Peter D. Arkwright, Siobhan O. Burns, Lucy S. K. Walker, David M. Sansom
Journal: Blood (2017)
The Functional Role of Microrna 15a/16-1 as Tumor Suppressor Genes in Multiple Myeloma.
Authors: Moshe E Gatt, Margaret Ebert, Mala Mani, Yunyu Zhang, Roi Gazit, Daniel E Carrasco, Jui Dutta, Sophia Adamia, Nikhil C. Munshi, Stéphane Minvielle, Herve Avet-Loiseau, Yu-Tzu Tai, Kenneth C. Anderson, Daniel Ruben Carrasco
Journal: Blood (2009)
PCSM-01INTEGRATING PATIENT SELF-REPORT DATA INTO THE NEURO-ONCOLOGY CLINIC EXPERIENCE: LESSONS LEARNED
Authors: Christina Amidei, Victoria Frazier-Warmack, Jean Arzbaecher, M. Kelly Nicholas
Journal: Neuro-Oncology (2015)

Patients with brain tumors may forget to mention symptoms during a clinic visit or think they are expected or unimportant. Time constraints in the clinic setting may also limit symptom identification. Lack of symptom identification may adversely affect quality of life and lead to missed opportunities for symptom management. To standardize symptom identification and facilitate symptom management, a patient self-report measure of symptom severity was incorporated into routine clinical care. As part of the initial implementation phase, 64 patients completed the self-report form. The most common and severe symptoms patients identified were fatigue (N = 53, 83%) trouble sleeping (N = 52, 81%), and trouble remembering (N = 49, 77%) and concentrating (N = 45, 70%). Although uncommon, seizures were very bothersome. Patients reported the questionnaire was easy to complete (N = 53, 83%), able to be completed within 5 minutes, and accurately reflected their experience (N = 44, 69%). In an audit of clinic visit documentation, 27 (42%) patients reported moderate to severe symptoms that were not identified during the clinic visit. The most common and bothersome symptoms were used to develop a patient education and self-management program and frame evidence-based interventions that could be delivered during the clinic visit, allowing the clinician to focus on individual symptom management. Challenges were encountered in linking patient self-report data to flow sheets and decision-making tools in the electronic medical records. Integrating patient self-report data into the clinic setting provides information that can be used to enhance symptom identification and management and promote patient-centered care.